Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative treatment for many malignant or non-malignant hematologic diseases. The preventive post-transplant treatment of these complications after allo-HSCT is based on immunosuppressive and anti-infective drugs and supplements (magnesium, folic acid). [1] [2] [3] Therefore, allo-HSCT recipients are discharged from hospital with prescriptions of several drugs to be taken once they return home. Some treatments should be continued for months or even years, especially in the case of graft-versus-host disease after allo-HSCT. Medication adherence was defined by Haynes et al. 4 as: 'the extent to which patients follow the instructions they are given for prescribed treatments'. In 2003, the World Health Organization described medication adherence as the most determining factor in the effectiveness of a treatment (http://www.who.int/chp/knowledge/publications/adherence_ report/en/ [Internet] . WHO. (cited 21 January 2017)). Medication adherence has been widely evaluated for solid organ transplantation where poor adherence to immunosuppressive drugs was reported among 19-25% of patients 5, 6 although in some studies this was as high as 50%. 7 In hematology setting, medication adherence has been particularly studied in chronic myeloid leukemia. The ADAGIO study reported a rate of 36% poor adherent patients to tyrosine kinase inhibitors, 8 whereas the rate was only 3% in a single-center study. 9 However, medication adherence among allo-HSCT recipients has not yet been characterized. 10 In 2015, a French report laid the emphasis on this lack of data. 11 On account of the large number of medications with significant side effects and anticipated link between high drug adherence and best possible transplant outcome, we conducted a pilot study to assess medication adherence among allo-HSCT recipients.
This observational single-center study was based on a selfadministered eight-item Medication Adherence Scale questionnaire completed by previously transplanted patients (at between 60 and 180 days post transplant). The study was conducted in the hematology department of Saint-Antoine Hospital between November 2015 and July 2016. Patients who were able to read and write and were ⩾ 18 years old were eligible to participate. Each patient was given an information leaflet by a specially trained pharmacist. Due to the observational, non-interventional nature of the study, with anonymized data, requirement for informed consent was waived while patient non-opposition was documented. The study was approved by the Ile-de-France III ethics committee (Comité_de_Protection_des_Personnes / ID RCB: 2015-A01710-49), and was registered with the French national data protection authority (Commission Nationale de l'informatique et des libertés: no. 1902621). As recommended, 12 the eightitem Medication Adherence Scale score could be calculated if the respondent answered at least 75% (6 of 8) of the questions. When a reply was missing, the median score of respondents to that item was substituted. Individual item scores were summed up and those patients with a score of 8 were considered high adherents to medication, whereas a poor medication adherence referred to a score under 8. Among poor adherents, medium adherence corresponded to a score of 6-8, while a score of o 6 was considered low adherence. Comparisons on categorical variables were performed with Fisher's exact test and those on continuous variables with Student's test. Statistical significance was reached if po0.05. Statistical analyzes were performed using R software (Version 0.98.1103-2009-2014 RStudio, Inc).
A total of 33 allo-HSCT recipients were included. Median age at transplantation of patients was 54 years (interquartile 46-63) and 60.6% (n = 20) were male ( Table 1 ). The youngest patient was 31 and the oldest one was 70 years. Median time from transplantation was 72 days (interquartile 65-95). Overall 28 patients (84.8%) received a reduced intensity conditioning regimen. The median number of prescribed drugs was 12 (interquartile [10] [11] [12] [13] [14] and 29 patients (88%) were being treated with oral cyclosporine at the time of the visit (as graft-versus-host disease prophylaxis). All patients answered at least 75% (6 of 8) of the questions. Most patients 94% (31/33) answered every question in the questionnaire, one did not answer two questions and another did not answer one question.
In this series, 54.6% (18/33) of patients were poorly adherent to their medications and 45.4% (15/33) were highly adherent. Figure 1 depicts the proportion of each adherence category. Among the 18 poorly adherent patients 6.1% (2/33) had low adherence (score o 6) and 48.5% (16/33) had medium adherence. The median score was 7.75/8, the minimum was 4.5 and 15 patients (45.4%) obtained optimal score (8/8). The results of the distribution of eight-item Medication Adherence Scale items showed that 36.4% patients answered 'YES' to the question: 'Taking medication every day is a real inconvenience for some people. Do you ever feel hassled about sticking to your treatment plan?', 3% declared having sometimes forgotten to take their medicines, and no patient had forgotten to take their medication the day before the visit. Finally, 15.2% declared to miss taking their medication for reasons than other forgetting.
The only socio-demographic characteristic significantly associated with medication adherence was age (P = 0.03) ( Table 1 ). The percentage of drug adherence increased significantly with the increase of the age of patients, with a Spearman's correlation coefficient equal to 0.47 (P o 0.05). Younger patients had a poorer adherence than older patients. Observation of medical data showed the number of prescribed drugs, outbreak of graft-versushost disease, diagnosis or disease status and time since transplantation were not associated with adherence.
This pilot study revealed that more than half (54.6%) of allo-HSCT patients were poorly adherent to medication. The proportion of poor adherence was higher than that reported in solid organ transplantation. [5] [6] [7] Complex prophylactic regimens after allo-HSCT (anti-infective and immunosuppressive drugs) challenge the ability to adhere to medication. Then doses, frequency and duration treatment tend to be adjusted every week and may increase the complexity and non-adherence. One third of patients felt hassled about sticking to their treatment plan, this suggests that patients probably become less committed to taking their medication as time lapses.
Older age was significantly associated with high adherence. Age has also been described in others studies to impact on medication adherence: younger patients are more lax in their medication behavior. 10 The fact that the number of prescribed drugs was not significantly associated with medication adherence in our study was surprising, because patients often reported feeling 'hassled' about taking too many medications in other series. 13 Our study suffers from some limitations. First, it was restricted to a single transplant center and is too small to draw substantial and generalizable conclusions. It is a pilot study and the results should be confirmed by a larger and multi-center study. Second, adherence was evaluated by a self-questionnaire, this method may be criticized because it is an indirect method which is susceptible to error. Patients can easily distort the results and overestimate the rate of medication adherence. The eight-item Medication Adherence Scale questionnaire is a simple and economical method, currently used by physicians in study or during consultation for other chronic diseases (e.g., cardiovascular, diabetes).
14 Indeed adherence rates differ according to the methods for measuring adherence: electronic monitoring, measurements of a biologic marker in the blood, pill count, selfreported questionnaires and clinicians' reports. In a future study on adherence in this population, a combination of methods should be used to confirm our observed medication adherence rate.
The impact of a poor medication adherence in solid organ transplantation can lead to relapse or graft loss 6 whereas a poor adherence in allo-HSCT recipients could cause major complications (graft-versus-host disease, renal failure and infections). For this reason, medication adherence remains a major focus for allo-HSCT patients. It is often difficult to enforce, because the side effects of some medications tend to discourage patients from taking their treatment when it includes these drugs. The problem is particularly challenging with prophylactic medication when the patient's condition is asymptomatic, the patients may not understand the reasons for these treatments. 10 The rate of poor adherence suggests that actions should be taken in order to improve medication adherence such as an improvement in the patients' knowledge of their disease and its treatment, as reported in a Belgian study. 8 This report is a first overview of adherence to medication among allo-HSCT recipients. Our results showed more than 50% of patients were poorly adherent to medication, and would tend to suggest that younger patients had a poorer adherence than older patients. This pilot study may be helpful to design a larger well-built multicenter study. Moreover, the identification of predicting factors may be useful to alert physicians to a patient's profile for poor adherence.
